Mangoceuticals (NASDAQ:MGRX) Announces Quarterly Earnings Results

Mangoceuticals (NASDAQ:MGRX) posted its quarterly earnings results on Wednesday. The company reported $0.13 earnings per share (EPS) for the quarter, Zacks reports. Mangoceuticals had a negative net margin of 4,253.43% and a negative return on equity of 114.63%. The company had revenue of $0.09 million during the quarter.

Mangoceuticals Stock Performance

Shares of NASDAQ MGRX opened at $0.34 on Friday. The firm has a fifty day moving average of $0.40 and a 200 day moving average of $1.14. The firm has a market cap of $5.51 million, a PE ratio of -0.13 and a beta of 2.54. Mangoceuticals has a one year low of $0.16 and a one year high of $2.88.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of MGRX. Armistice Capital LLC purchased a new position in Mangoceuticals in the 4th quarter valued at about $1,137,000. Ikarian Capital LLC acquired a new position in shares of Mangoceuticals during the fourth quarter valued at approximately $102,000. Jane Street Group LLC acquired a new position in shares of Mangoceuticals during the fourth quarter valued at approximately $35,000. Boothbay Fund Management LLC purchased a new position in shares of Mangoceuticals in the fourth quarter valued at approximately $28,000. Finally, Virtu Financial LLC acquired a new stake in shares of Mangoceuticals in the fourth quarter worth approximately $25,000. Institutional investors and hedge funds own 56.72% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mangoceuticals in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Mangoceuticals Company Profile

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.